Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma

NCT ID: NCT00690898

Last Updated: 2022-10-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 108 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-05-31
• Study Completion Date: 2012-02-29

Brief Summary

Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.

The disease develops insidiously, causing a gradual progression of symptoms; consequently most patients are diagnosed in their fourth decade of life.

Administration of somatostatin analogues such as lanreotide have been shown to result in normalisation or the decrease of GH and insulin growth factor (IGF-1) levels and improvement of clinical symptoms in acromegalic patients. The purpose of this study is to evaluate whether lanreotide is also effective on tumour volume reduction (tumour shrinkage) and the benefits of this potential tumour shrinkage on disease symptoms and patient's quality of life.

Conditions

Acromegaly

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lanreotide autogel 120 mg

Group Type: EXPERIMENTAL

Lanreotide autogel 120 mg

Intervention Type: DRUG

12 months

Interventions

Lanreotide autogel 120 mg

12 months

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• The patient has given written informed consent prior to any study related procedures
• The patient is male or female and is aged between 18 and 75 years, inclusive,
• Diagnosis of acromegaly defined by i) GH nadir > 1 ng/mL as assessed by an oral glucose tolerance test for non diabetic patients (central laboratory results) or a mean GH level > 1 ng/mL based on 5 samples taken every 10 to 15 minutes for diabetic patients ( central laboratory results) AND ii) IGF-1 concentrations elevated above the age- and sex-matched normal range for diabetic and non diabetic patients (central laboratory results),
• The patient has a pituitary adenoma with a diameter greater than or equal to 10 mm based on Magnetic Resonance Imaging (MRI) central reading,
• The patient has no visual field defect identified at the visual evaluation, performed by Goldman Visual Fields Analyser and Automated visual field static perimeter, except visual field abnormality at the time of screening and that is in the investigator's Clinical judgement:

• Not related to the pituitary adenoma
• Clinically stable condition not presumed to change during the study period
• Not modifying the ability to evaluate visual field changes related to the macroadenoma

Exclusion Criteria

• The patient has a history of hypersensitivity to Lanreotide or drugs with a similar chemical structure,
• The patient has received any unlicensed drug within the 30 days prior to the screening visit or is scheduled to receive an unlicensed drug during the course of the study,
• The patient is likely to require treatment during the study with somatostatin analogues other than Lanreotide Autogel 120 mg, dopamine agonist, GH receptor antagonist (pegvisomant), and Cyclosporine or drugs that are not permitted by the study protocol,
• The patient is a female at risk of pregnancy during the study and is not using acceptable contraceptive methods. Females of childbearing potential must provide a negative pregnancy test at start of study and must be using oral, double barrier (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide), injectable contraception or an intra uterine device. Non childbearing potential is defined as post-menopause for at least 1 year, surgical sterilisation or hysterectomy at least three months before the start of the study,
• The patient is pregnant or lactating,
• The patient has a history of, or known current, problems with alcohol abuse,
• The patient has any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.
• The patient has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the patient's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study,
• The patient has undergone pituitary surgery or pituitary radiotherapy prior to study entry,
• The patient has previously been treated with a somatostatin analogue,
• The patient has received a dopamine agonist or a GH receptor antagonist (pegvisomant) prior to study entry,
• The patient is expected to require pituitary surgery (adenomectomy) or to receive radiotherapy during the study period,
• Patients with suspected associated prolactinoma: prolactin level > 100 ng/mL (central laboratory results),
• Patient is allergic to Gadolinium (MRI contrast agent) or has acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2),
• Patient known by Investigator, to have congenital or acquired optic nerve disease or any visual abnormality with risk of worsening during the course of the study (e.g glaucoma), influencing ability to evaluate Visual Field changes related to the macroadenoma.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ipsen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ipsen Medical Director

Role: STUDY_DIRECTOR

Ipsen

Locations

University Hospital Antwerpen

Edegem, , Belgium

Všeobecná fakultní nemocnice, Karlova Univerzita

Prague, , Czechia

Helsinki University Center Hospital

Helsinki, , Finland

The Turku University Central Hospital

Turku, , Finland

Hopital De Bois Guillaume

Bois-Guillaume, , France

CHU Henri Mondor

Créteil, , France

CHU Grenoble Albert Michallon

Grenoble, , France

CHRU Lille Hopital Claude Huriez

Lille, , France

Groupement Hospitalier Est

Lyon, , France

Hôpital de la Timone

Marseille, , France

Hôpital Bicêtre

Paris, , France

Hopital Haut Leveque

Pessac, , France

CHU de Reims, Hopital Robert Debré

Reims, , France

Friedrich-Alexander University

Erlangen, , Germany

Universitatsklinikum Essen

Essen, , Germany

Klinikum der Johann Wolfgang Goethe-Universität

Frankfurt, , Germany

ENDOC Zentrum für Endokrine Tumoren und Praxis für Endokrinologie, Andrologie und medikamentöse Tumortherapie

Hamburg, , Germany

Medizinische Klinik Innenstadt

München, , Germany

AOU Policlinico "G. Martino" Messina

Messina, , Italy

Università Federico II di Napoli, Dipartimento di Endocrinologia Molecolare e Clinicae Oncologia

Napoli, , Italy

Università Cattolica del Sacro Cuore, Policlinico A. Gemelli, U.O.C. di Endocrinologia

Roma, , Italy

ERASMUS MC Rotterdam

Rotterdam, , Netherlands

UMC Utrecht

Utrecht, , Netherlands

Cerrahpasa Medical Facility

Istanbul, , Turkey (Türkiye)

27/28 Aberdeen Royal Infirmary

Aberdeen, , United Kingdom

Christie Hospital

Manchester, , United Kingdom

Derriford Hospital

Plymouth, , United Kingdom

Countries

Belgium; Czechia; Finland; France; Germany; Italy; Netherlands; Turkey (Türkiye); United Kingdom

References

Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Prevost G, Maisonobe P, Clermont A; PRIMARYS Investigators. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab. 2014 Apr;99(4):1282-90. doi: 10.1210/jc.2013-3318. Epub 2013 Jan 1.

Reference Type: RESULT

PMID: 24423301 (View on PubMed)

Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, Webb SM; PRIMARYS Investigators Group. Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary. 2016 Apr;19(2):149-57. doi: 10.1007/s11102-015-0693-y.

Reference Type: DERIVED

PMID: 26603536 (View on PubMed)

Other Identifiers

2007-000155-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2-79-52030-207

Identifier Type: -

Identifier Source: org_study_id

NCT00225134

Identifier Type: -

Identifier Source: nct_alias